[1] SAYER A A, COOPER R, ARAI H, et al. Sarcopenia[J]. Nat Rev Dis Primers, 2024, 10(1): 68. [2] DAMLUJI A A, ALFARAIDHY M, ALHAJRI N, et al. Sarcopenia and cardiovascular diseases[J]. Circulation, 2023, 147(20): 1534-1553. [3] BENZ E, PINEL A, GUILLET C, et al. Sarcopenia and sarcopenic obesity and mortality among older people[J]. JAMA Netw Open, 2024, 7(3): e243604. [4] GUI M, LV L, HU S, et al. Sarcopenia in Parkinson’s disease: from pathogenesis to interventions[J]. Metabolism, 2025, 169: 156272. [5] CHINVATTANACHOT G, RIVAS D, DUQUE G. Mechanisms of muscle cells alterations and regeneration decline during aging[J]. Ageing Res Rev, 2024, 102: 102589. [6] ROBERTS G K, STOUT M D. Specifications for the conduct of toxicity studies by the division of translational toxicology at the National Institute of Environmental Health Sciences[M]. Research Triangle Park: National Institute of Environmental Health Sciences, 2023. [7] KONG D Z, ZHANG X Z, LU Y, et al. Jian-pi Qu-tan Hua-yu decoction improves oxidative stress-induced inflammation in endothelial cells in atherosclerotic ApoE-/- mice through the NOX1-ROS-ERK1/2 pathway[J]. Phytomedicine, 2025, 143: 156815. [8] LIU C, WONG P Y, WANG Q, et al. Short-chain fatty acids enhance muscle mass and function through the activation of mTOR signalling pathways in sarcopenic mice[J]. J Cachexia Sarcopenia Muscle, 2024, 15(6): 2387-2401. [9] LARSSON L, DEGENS H, LI M, et al. Sarcopenia: aging-related loss of muscle mass and function[J]. Physiol Rev, 2019, 99(1): 427-511. [10] CRUZ-JENTOFT A J, BAHAT G, BAUER J, et al. Sarcopenia: revised European consensus on definition and diagnosis[J]. Age Ageing, 2019, 48(1): 16-31. [11] SHAFIEE G, KESHTKAR A, SOLTANI A, et al. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies[J]. J Diabetes Metab Disord, 2017, 16(1): 21. [12] YUAN S, LARSSON S C. Epidemiology of sarcopenia: prevalence, risk factors, and consequences[J]. Metabolism, 2023, 144: 155533. [13] HASHIMOTO Y, TAKAHASHI F, OKAMURA T, et al. Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes[J]. Metabolism, 2023, 144: 155585. [14] GUO M, YAO J, LI J, et al. Irisin ameliorates age-associated sarcopenia and metabolic dysfunction[J]. J Cachexia Sarcopenia Muscle, 2023, 14(1): 391-405. [15] D’ONOFRIO G, KIRSCHNER J, PRATHER H, et al. Musculoskeletal exercise: its role in promoting health and longevity[J]. Prog Cardiovasc Dis, 2023, 77: 25-36. [16] BRIGHTWELL C R, MARKOFSKI M M, MORO T, et al. Moderate-intensity aerobic exercise improves skeletal muscle quality in older adults[J]. Transl Sports Med, 2019, 2(3): 109-119. [17] PROSKE U, MORGAN D L. Muscle damage from eccentric exercise: mechanism, mechanical signs, adaptation and clinical applications[J]. J Physiol, 2001, 537(Pt 2): 333-345. [18] TEE J C, BOSCH A N, LAMBERT M I. Metabolic consequences of exercise-induced muscle damage[J]. Phys Med, 2007, 37(10): 827-836. [19] MIEDEL E L, BRISSON B K, HAMILTON T, et al. Type III collagen modulates fracture callus bone formation and early remodeling[J]. J Orthop Res, 2015, 33(5): 675-684. [20] ROSIN N L, WINSTONE T M L, KELLEY M, et al. Targeted proteomic approach for quantification of collagen type I and type III in formalin-fixed paraffin-embedded tissue[J]. Sci Rep, 2024, 14(1): 17769. [21] KWON J W, LEE W J, PARK S B, et al. Generalized joint hypermobility in healthy female koreans: prevalence and age-related differences[J]. Ann Rehabil Med, 2013, 37(6): 832-838. [22] RHIBI F, ZOUHAL H, LIRA F S, et al. Inflammatory cytokines and metabolic responses to high-intensity intermittent training: effect of the exercise intensity[J]. Biol Sport, 2022, 39(2): 263-272. |